Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.

MLA

González, M., et al. “Pretreatment Characteristics and Clinical Outcome of Acute Promyelocytic Leukaemia Patients According to the PML-RAR Alpha Isoforms: A Study of the PETHEMA Group.” British Journal of Haematology, vol. 114, no. 1, July 2001, pp. 99–103. EBSCOhost, https://doi.org/10.1046/j.1365-2141.2001.02915.x.

APA

González, M., Barragán, E., Bolufer, P., Chillón, C., Colomer, D., Borstein, R., Calasanz, M. J., Gómez-Casares, M. T., Villegas, A., Marugán, I., Román, J., Martín, G., Rayón, C., Debén, G., Tormo, M., Díaz-Mediavilla, J., Esteve, J., González-San Miguel, J., Rivas, C., … Sanz, M. A. (2001). Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. British Journal of Haematology, 114(1), 99–103. https://doi.org/10.1046/j.1365-2141.2001.02915.x

Chicago

González, M, E Barragán, P Bolufer, C Chillón, D Colomer, R Borstein, M J Calasanz, et al. 2001. “Pretreatment Characteristics and Clinical Outcome of Acute Promyelocytic Leukaemia Patients According to the PML-RAR Alpha Isoforms: A Study of the PETHEMA Group.” British Journal of Haematology 114 (1): 99–103. doi:10.1046/j.1365-2141.2001.02915.x.